3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
112
Recurrence
29
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Neoplasms
14
Neoplasms, Plasma Cell
13
Leukemia
10
Lymphoma, Non-Hodgkin
8
Lymphoma
8
Leukemia, Myeloid, Acute
8
Carcinoma, Non-Small-Cell Lung
8
Lymphoma, Large B-Cell, Diffuse
7
Burkitt Lymphoma
7
Vomiting
6
Prostatic Neoplasms
6
Breast Neoplasms
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Nausea
5
Lung Neoplasms
5
Pancreatic Neoplasms
3
Lymphoma, Follicular
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Glioblastoma
3
Amyloidosis
3
Smoldering Multiple Myeloma
2
Renal Insufficiency
2
Oligodendroglioma
2
Myelodysplastic Syndromes
2
Interventions
pembrolizumab
11
epacadostat
2
Paclitaxel
2
spartalizumab
1
ribociclib
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Gemcitabine
1
Docetaxel
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Axitinib
1
AZD 6244
1
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dexamethasone
×
Clear all
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts